Topic: Chutes and Ladders
NGM Bio gains a Genentech/Lilly vet as R&D chief; Forma nabs a Genentech commercial exec as CEO; and Nimbus builds out its biology and preclinical teams.
Drug accelerator Cydan is hiring on Yongchang Qiu, Ph.D., as vice president of preclinical development and Ryan Tyler, Ph.D., as senior director of preclinical research.
Nimbus promoted Jennifer Rocnik, Ph.D., to vice president of biology and Alan Collis, Ph.D., will serve as vice president of preclinical development.
Novartis' Sandoz chief exits; NCI director to serve as interim FDA head; C4 poaches new CMO; and Karuna hires another ex-Lilly scientist.
FDA chief Scott Gottlieb steps down; Gilead loses oncology leader; Deciphera CEO to retire; and DBV loses two executives ahead of peanut drug refile.
Former Biogen executive Priya Singhal has joined Zafgen as its new head of R&D after helping shepherd several Biogen programs toward approvals.
Daiichi Sankyo makes changes to its U.S. research unit; Immunomedics' CEO quits; and Parexel nabs another key FDA oncology staffer.
Enzyvant finds new CEO in former Alexion exec; Arix reappoints CEO after 5-month hunt; and MorphoSys CEO Moroney announces retirement.
Rachelle Jacques, who most recently was a senior vice president at Alexion, takes over from Alvin Shih, M.D., who signed on at Enzyvant in November 2016.
Moroney will step down as CEO after his current contract expires in June 2020, or earlier if a successor is appointed before that time.